Structural basis for the autoinhibition of c-Abl tyrosine kinase

Cell

Volumn 112, Issue 6, 2003, Pages 859-871

  Nagar, Bhushan ^a   Hantschel, Oliver ^c   Young, Matthew A ^a   Scheffzek, Klaus ^d   Veach, Darren ^f   Bornmann, William ^f   Clarkson, Bayard ^f   Superti Furga, Giulio ^c,e   Kuriyan, John ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c Developmental Biology   (Germany)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^e GLAXOSMITHKLINE   (United Kingdom)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE;

ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; PRIORITY JOURNAL; SRC HOMOLOGY DOMAIN;

RUMEX;

EID: 0344626926     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)00194-6     Document Type: Article

References (40)

1. Azam M., Latek R.R., Daley G.Q. Mechanisms of STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843. this issue,
2. Barila D., Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18:1998;280-282.
3. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory sites. J. Biol. Chem. 275:2000;35631-35637.
4. Brasher B.B., Roumiantsev S., Van Etten R.A. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene. 20:2001;7744-7752.
5. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography & NMR system. A new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921.
6. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M. Jr., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., Kollman P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117:1995;5179-5197.
7. DeLano W.L. The PyMOL User's Manual. 2002;Delano Scientific, San Carlos, CA.
8. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
9. Franz W.M., Berger P., Wang J.Y. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8:1989;137-147.
10. Fushman D., Xu R., Cowburn D. Direct determination of changes of interdomain orientation on ligation. use of the orientational dependence of 15N NMR relaxation in Abl SH(32) Biochemistry. 38:1999;10225-10230.
11. Gangal M., Clifford T., Deich J., Cheng X., Taylor S.S., Johnson D.A. Mobilization of the A-kinase N-myristate through an isoform-specific intermolecular switch. Proc. Natl. Acad. Sci. USA. 96:1999;12394-12399.
12. Goga A., McLaughlin J., Pendergast A.M., Parmar K., Muller A., Rosenberg N., Witte O.N. Oncogenic activation of c-ABL by mutation within its last exon. Mol. Cell. Biol. 13:1993;4967-4975.
13. Hantschel O., Nagar B., Guettler S., Kretzschmar J., Dorey K., Kuriyan J., Superti-Furga G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 112:2003;845-857. this issue,
14. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282.
15. Jackson P., Baltimore D. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8:1989;449-456.
16. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
17. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26:1993;795-800.
18. Koegl M., Courtneidge S.A., Superti-Furga G. Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk. Oncogene. 11:1995;2317-2329.
19. Kraker A.J., Hartl B.G., Amar A.M., Barvian M.R., Showalter H.D., Moore C.W. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 60:2000;885-898.
20. Kuriyan J., Cowburn D. Modular peptide binding domains. Annu. Rev. Biophys. Biomol. Struct. 26:1997;259-288.
21. Muller A.J., Pendergast A.M., Parmar K., Havlik M.H., Rosenberg N., Witte O.N. En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase. Proc. Natl. Acad. Sci. USA. 90:1993;3457-3461.
22. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
23. Nam H.J., Haser W.G., Roberts T.M., Frederick C.A. Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism. Structure. 4:1996;1105-1114.
24. Navaza J. AMoRe. an automated package for molecular replacement Acta. Crystallogr. A. 50:1994;157-163.
25. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
26. Pluk H., Dorey K., Superti-Furga G. Autoinhibition of c-Abl. Cell. 108:2002;247-259.
27. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
28. Sawyers C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 1:2002;13-15.
29. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell. 3:1999;639-648.
30. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
31. Superti-Furga G., Courtneidge S.A. Structure-function relationships in Src family and related protein kinases. Bioessays. 17:1995;321-330.
32. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13:1997;513-609.
33. Van Etten R.A. Cycling, stressed-out and nervous. cellular functions of c-Abl Trends Cell Biol. 9:1999;179-186.
34. Williams J.C., Weijland A., Gonfloni S., Thompson A., Courtneidge S.A., Superti-Furga G., Wierenga R.K. The 2.35 Å crystal structure of the inactivated form of chicken Src. a dynamic molecule with multiple regulatory interactions J. Mol. Biol. 274:1997;757-775.
35. Wisniewski D., Lambek C.L., Liu C., Strife A., Veach D.R., Nagar B., Young M.A., Schindler T., Bornmann W.G., Bertino J.R.et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62:2002;4244-4255.
36. Woodring P.J., Hunter T., Wang J.Y. Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J. Biol. Chem. 276:2001;27104-27110.
37. Xu W., Doshi A., Lei M., Eck M.J., Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell. 3:1999;629-638.
38. Yamaguchi H., Hendrickson W.A. Structural basis for activation of the human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 384:1996;484-489.
39. Young M.A., Gonfloni S., Superti-Furga G., Roux B., Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 105:2001;115-126.
40. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B. Potent and selective inhibitors of the Abl-kinase. phenylamino-pyrimidine (PAP) derivatives Bioorg. Med. Chem. Lett. 7:1997;187-192.